-
Advancing breakthrough biotechnologies: bringing innovative treatment modalities to patients suffering from diseases with limited pharmacological options.
We partner with inventors, research centers, and academic institutions leveraging our decades of experience and deep industry relationships to rapidly move novel therapeutic compounds into and through clinical development towards FDA approval.
Our Founders
Raised in excess of $2 billion
7 drugs approved by FDA
80 years combined experience financing biotech
Past and Current Partners & Affiliates
- Massachusetts Institute of Technology
- Mayo Clinic
- Memorial Sloan Kettering Cancer Center
- MD Anderson
- Washington University at St. Louis
- University of New Mexico
- Rutgers University
- NIH/NCI
- Veterans Health Administration
- University of Miami
- Moffitt Cancer Center
- University of Florida
- Roswell Park Cancer Institute
- Hebrew University
- University of San Francisco
- University of Pennsylvania
- John Hopkins
- Weizmann Institute
- University of Alabama
- Pittsburgh University
- Princeton University
Past Partner Deals
Pipeline
Camelot’s pipeline includes therapeutics from inventors, research centers, academic institutions, and other companies around the globe. Our expertise is in oncology, neurologic disease, and orphan disease advancements.